119 related articles for article (PubMed ID: 38227839)
1. A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.
Makihara K; Yamamoto Y; Miyazaki M; Taguchi M; Sato J; Takase H; Uezono Y
J Pain Palliat Care Pharmacother; 2024 Mar; 38(1):3-12. PubMed ID: 38227839
[TBL] [Abstract][Full Text] [Related]
2. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
[TBL] [Abstract][Full Text] [Related]
4. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
5. Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.
Decaix T; Gautier S; Royer L; Laprévote O; Tritz T; Siguret V; Teillet L; Sellier C; Pépin M
Aging Clin Exp Res; 2023 Nov; 35(11):2471-2481. PubMed ID: 37861957
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.
Tsukuura H; Miyazaki M; Morita T; Sugishita M; Kato H; Murasaki Y; Gyawali B; Kubo Y; Ando M; Kondo M; Yamada K; Hasegawa Y; Ando Y
Oncologist; 2018 Mar; 23(3):367-374. PubMed ID: 29038236
[TBL] [Abstract][Full Text] [Related]
7. Influence of Concomitant Polypharmacy on Docetaxel-induced Febrile Neutropenia.
Makihara K; Shimeda Y; Matsumura T
Cancer Diagn Progn; 2021; 1(3):135-141. PubMed ID: 35399310
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Nausea and Vomiting Frequency Following Opioid Dose Escalation and Its Risk Factors: A Single-Center Retrospective Observational Study.
Yamamoto Y; Yamamoto S; Tsuge T; Urano K; Matsuura K
J Palliat Med; 2024 Mar; 27(3):301-306. PubMed ID: 37733255
[No Abstract] [Full Text] [Related]
10. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.
Mannheimer B; von Bahr C; Pettersson H; Eliasson E
Ther Drug Monit; 2008 Oct; 30(5):565-9. PubMed ID: 18728628
[TBL] [Abstract][Full Text] [Related]
11. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
12. The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients.
Kim JH; Kim JY; Lee N; Yee J; Gwak HS
J Clin Pharm Ther; 2020 Oct; 45(5):976-982. PubMed ID: 32068910
[TBL] [Abstract][Full Text] [Related]
13. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.
Davies SJ; Eayrs S; Pratt P; Lennard MS
Br J Clin Pharmacol; 2004 Apr; 57(4):464-72. PubMed ID: 15025745
[TBL] [Abstract][Full Text] [Related]
14. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
15. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
17. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.
Monte AA; Heard KJ; Campbell J; Hamamura D; Weinshilboum RM; Vasiliou V
Acad Emerg Med; 2014 Aug; 21(8):879-85. PubMed ID: 25156930
[TBL] [Abstract][Full Text] [Related]
18. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Yunusa I; Gagne JJ; Yoshida K; Bykov K
JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
